Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells

Autor: Sosman, JA, Oettel, KR, Smith, SD, Hank, JA, Fisch, P, Sondel, PM

Publikováno v: Blood; May 1990, Vol. 75 Issue: 10 p2005-2016, 12p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Autor: Pennell NA; Cleveland Clinic, Cleveland, OH., Dillmon M; Harbin Clinic LLC, Rome, GA., Levit LA; American Society of Clinical Oncology, Alexandria, VA., Moushey EA; American Society of Clinical Oncology, Alexandria, VA., Alva AS; University of Michigan, Ann Arbor, MI., Blau S; Northwest Medical Specialties, Seattle, WA., Cannon TL; INOVA Medical Group, Fairfax, VA., Dickson NR; Tennessee Oncology, Nashville, TN., Diehn M; Stanford University, Stanford, CA., Gonen M; Memorial Sloan-Kettering Cancer Center, New York, NY., Gonzalez MM; Virginia Mason Medical Center, Seattle, WA., Hensold JO; Bozeman Deaconess Health Services, Bozeman, MT., Hinyard LJ; Saint Louis University, St Louis, MO., King T; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA., Lindsey SC; Cholangiocarcinoma Foundation, Herriman, UT., Magnuson A; University of Rochester, Rochester, NY., Marron J; Boston Children's Hospital, Boston, MA., McAneny BL; New Mexico Oncology Hematology Consultants, Ltd, Albuquerque, NM., McDonnell TM; Seattle Cancer Care Alliance, Seattle, WA., Mileham KF; Levine Cancer Institute, Charlotte, NC., Nasso SF; National Coalition for Cancer Survivorship, Silver Spring, MD., Nowakowski GS; Mayo Clinic, Rochester, MN., Oettel KR; Gundersen Health System, La Crosse, WI., Patel MI; Stanford University, Stanford, CA., Patt DA; Texas Oncology PA, Austin, TX., Perlmutter J; Gemini Group, Ann Arbor, MI., Pickard TA; University of Texas MD Anderson Cancer Center, Houston, TX., Rodriguez G; START Center for Cancer Care, San Antonio, TX., Rosenberg AR; University of Washington, Seattle, WA., Russo B; The Center for Cancer and Blood Disorders, Fort Worth, TX., Szczepanek C; Cancer Research Consortium of West Michigan NCORP, Grand Rapids, MI., Smith CB; Icahn School of Medicine at Mt. Sinai, Bronxville, NY., Srivastava P; Kaiser Permanente Northern California, Walnut Creek, CA., Teplinsky E; Valley Health System, Paramus, NJ., Thota R; Intermountain Healthcare, South Jordan, UT., Traina TA; Memorial Sloan-Kettering Cancer Center, New York, NY., Zon R; Michiana Hematology Oncology, Niles, MI., Bourbeau B; American Society of Clinical Oncology, Alexandria, VA., Bruinooge SS; American Society of Clinical Oncology, Alexandria, VA., Foster S; Association for Clinical Oncology, Alexandria, VA., Grubbs S; American Society of Clinical Oncology, Alexandria, VA., Hagerty K; Association for Clinical Oncology, Alexandria, VA., Hurley P; American Society of Clinical Oncology, Alexandria, VA., Kamin D; American Society of Clinical Oncology, Alexandria, VA., Phillips J; American Society of Clinical Oncology, Alexandria, VA., Schenkel C; American Society of Clinical Oncology, Alexandria, VA., Schilsky RL; American Society of Clinical Oncology, Alexandria, VA., Burris HA 3rd; Sarah Cannon, Nashville, TN.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jan 10; Vol. 39 (2), pp. 155-169. Date of Electronic Publication: 2020 Dec 08.

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Autor: Hoang T; University of Wisconsin Carbone Cancer Center, Madison, WI, USA, txh@medicine.wisc.edu., Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM

Publikováno v: Investigational new drugs [Invest New Drugs] 2014 Feb; Vol. 32 (1), pp. 195-9. Date of Electronic Publication: 2013 Jun 01.